Hepato Cellular Carcinoma (HCC) Clinical Trials

34 clinical trials for Hepato Cellular Carcinoma (HCC) across international registries, including 19 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• LEOPARD Training and Validation Data Collection Study — RECRUITING
• LEOPARD Prospective Validation Cohort 1 — RECRUITING
• The Impact of Anaesthesia and Sedation on Inflammation and NETosis in Hepatocellular Carcinoma Ablation — RECRUITING · NA
• Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC) — RECRUITING · NA
• Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab — RECRUITING · PHASE2
• SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin — RECRUITING · PHASE2
• PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC) — RECRUITING · NA
• Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma — RECRUITING · PHASE2
• A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma — RECRUITING · PHASE2
• IIT2025-03-YANG-LIFT-HCC — RECRUITING · PHASE2
• Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma — RECRUITING · PHASE2
• Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC — RECRUITING · PHASE3
• Hepatocellular Carcinoma Identification Using Delta-HLD — RECRUITING
• Effect and Mechanism of ALPPS Operation on Liver Regeneration — RECRUITING
• Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma — RECRUITING
• PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma — RECRUITING
• HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence — RECRUITING · PHASE2
• PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC — RECRUITING · PHASE2
• A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA — RECRUITING · PHASE3
• Ebastine for Adjuvant Treatment of Tumor Budding-Positive Liver Cancer After Surgery — NOT_YET_RECRUITING · PHASE4
• Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer — NOT_YET_RECRUITING
• Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer — NOT_YET_RECRUITING
• Evaluation Of The Influence Of Anesthetic Interventions On The Evolution Of Hepatic Neoplastic Processes — COMPLETED · NA
• Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE — COMPLETED · PHASE4
• Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC — NOT_YET_RECRUITING · PHASE2
• TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk — NOT_YET_RECRUITING · PHASE2
• Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection — NOT_YET_RECRUITING · PHASE3
• BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma — WITHDRAWN · PHASE1
• Retrospective Clinical Validation of HepatoPredict — NOT_YET_RECRUITING
• Evaluate the Effect of Tirazamine on Primary Liver Cancer. — TERMINATED · PHASE1
• Ex-vivo Hypotermic Perfusion in Patients With Hepatocellular Carcinoma to Reduce the Incidence of Tumor Recurrence — COMPLETED
• Novel Biomarker Assay for Biomarker Assay for HCC Detection — OTHER
• PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, ACTIVE-CONTROLLED, CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LENVATINIB (E7080/MK-7902) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) VERSUS LENVATINIB IN FIRST-LINE THERAPY OF PARTICIPANTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (LEAP-002) — COMPLETED · PHASE3
• First Line Hepato Cellular Carcinoma (HCC) — COMPLETED · PHASE3

Refine this search